The genetic epidemiology of neurodegenerative disease
Open accessThe DOI matches its Crossref record; 103 of the 106 references it cites were found in a registry or an index.
Abstract
Gene defects play a major role in the pathogenesis of degenerative disorders of the nervous system.In fact, it has been the very knowledge gained from genetic studies that has allowed the elucidation of the molecular mechanisms underlying the etiology and pathogenesis of many neurodegenerative disorders.In this review, we discuss the current status of genetic epidemiology of the most common neurodegenerative diseases: Alzheimer disease, Parkinson disease, Lewy body dementia, frontotemporal dementia, amyotrophic lateral sclerosis, Huntington disease, and prion diseases, with a particular focus on similarities and differences among these syndromes. The complexities of common diseasesFamilial aggregation had been recognized as a prominent characteristic of many neurodegenerative disorders decades before the underlying molecular genetic or biochemical properties were known.It was often the identification of specific, disease-segregating mutations in previously unknown genes that directed the attention to certain proteins and pathways that are now considered crucial in the pathogenesis of these diseases.These include mutations in the β-amyloid (Aβ) precursor protein, causing Alzheimer disease (AD); in α-synuclein, causing Parkinson disease (PD); or in microtubule-associated protein tau, causing frontotemporal dementia (FTD) with parkinsonism.Another feature observed in most common neurodegenerative diseases -as well as in other common disorders -is a dichotomy between familial (rare) and seemingly nonfamilial (common) forms.The latter are also frequently described as "sporadic" or "idiopathic," although there is a growing body of evidence suggesting that a large proportion of these cases are also significantly influenced by genetic factors.These risk genes are likely to be numerous, displaying intricate patterns of interaction with each other as well as with nongenetic variable, and -unlike classical Mendelian ("simplex") disorders -exhibit no simple or single mode of inheritance.Hence, the genetics of these diseases has been labeled "complex."A popular conception regarding the genetic makeup of complex diseases is the "common disease/common variant" (CD/CV) hypothesis (1).According to this theory common disorders are also governed by common DNA variants (such as single nucleotide polymorphisms.These variants significantly increase disease risk but are insufficient to actually cause a specific disorder.Current empirical and theoretical data support this hypothesis, although there remains great uncertainty as to the number of the underlying risk factors and their specific effect sizes.In this context, it is noteworthy that even recent genetic advances in the study of complex diseases such as AD or diabetes likely only represent the most obvi-ous, most extreme cases of the underlying risk spectrum (Figure 1; ref.2).In AD, for instance, rare, fully penetrant autosomal dominant mutations in 3 genes (i.e.APP, PSEN1, and PSEN2) have been shown to cause the disease, while a common, incompletely penetrant susceptibility variant (i.e., ε4 in APOE; see below) significantly increases the risk for AD.The identification of these genes early in the study of AD genetics was possible due to the combination of several favorable circumstances, such as the presence of multiple independent mutations in the same locus and the availability of extended, multigenerational pedigrees for DNA genotyping and sequencing (in the case of PSEN1) or a large attributable fraction to the overall genetic variance, resulting from relatively high allele frequency and pronounced effect size (in the case of APOE).However, identification of disease genes that make smaller overall contributions to the genetic spectrum (because of only few mutational events; e.g., PSEN2), or risk factors with smaller effect sizes (i.e.odds ratios [ORs] ranging between 2 and 3), will require much larger samples and possibly more sensitive and efficient analytic tools to enable consistent detection across study populations (2).Additional, and commonly cited, problems in finding complex disease genes beyond the most obvious are multiple testing, publication bias, and questionable replication (3-5).Multiple testing can be placed under the larger category of "avoidable false positive" findings, which are also caused by testing insufficiently sized samples, using inappropriate matching of cases versus controls, stratifying populations, and choosing inadequate analysis strategies, etc. Publication bias, on the other hand, which indicates the higher a priori likelihood of a positive finding being published as opposed to a negative one, may have been a possible source of serious bias in the early days.However, there is only relatively little empirical evidence that publication bias actually represents a common or significant source of error in current publications investigating the genetics of a number of disorders (e.g., refs.6-12).The sheer number of publications in the AD gene
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Elevated levels of Amyloid-β (Aβ) peptide initiates a cascade of events that ultimately result in Alzheimer’s disease (AD) [1–4].”
From Amyloid-β interrupts canonical Sonic hedgehog signaling by distorting primary cilia structure (2018) · cites this paper as [4]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
MACDONALD, M. (1993) · Cell · doi:10.1016/0092-8674(93)90585-e · Cited by 8,366
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240
Rosen, D. R., Siddique, T., Patterson, D., Figlewicz, D. A., Sapp, P., Hentati, A., Donaldson, D., Goto, J., O'Regan, J. P., Deng, H.-X., et al. (1993) · Nature · doi:10.1038/362059a0 · Cited by 7,062
Prusiner, S. B. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.23.13363 · Cited by 5,373
Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism
Kitada, T., Asakawa, S., Hattori, N., Matsumine, H., Yamamura, Y., Minoshima, S., Yokochi, M., Mizuno, Y., & Shimizu, N. (1998) · Nature · doi:10.1038/33416 · Cited by 5,227 · cited 4×
“The most frequently involved gene in recessive parkinsonism is parkin (PRKN) on chromosome 6q25 (33, 41), which causes nearly half of all early-onset PD cases.”
BackgroundInfluentialGoate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659 · cited 5×
“In AD, for instance, rare, fully penetrant autosomal dominant mutations in 3 genes (i.e. APP, PSEN1, and PSEN2) have been shown to cause the disease, while a common, incompletely penetrant susceptibility variant (i.e., ε4 in APOE; see below) significantly increases the risk for AD.”
BackgroundInfluentialα-Synuclein Locus Triplication Causes Parkinson's Disease
Singleton, A. B., Farrer, M., Johnson, J., Singleton, A., Hague, S., Kachergus, J., Hulihan, M., Peuralinna, T., Dutra, A., Nussbaum, R., et al. (2003) · Science · doi:10.1126/science.1090278 · Cited by 4,383
Strittmatter, W. J., Saunders, A. M., Schmechel, D., Pericak-Vance, M., Enghild, J., Salvesen, G. S., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.5.1977 · Cited by 4,268 · cited 1×
“AD APP (15) Aβ precursor protein 21q21 Dominant Altered Aβ production (Aβ42/Aβ40 ratio ↑) and aggregation AD APOE (21, 22) Apolipoprotein E 19q13 Risk factor Unknown (Aβ aggregation? lipid metabolism?) AD PSEN1 (16) Presenilin 1 14q24 Dominant Altered Aβ production (Aβ42/Aβ40 ratio ↑) AD PSEN2 (17, 18) Presenilin 2 1q…”
BackgroundCloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease
Sherrington, R., Rogaev, E. I., Liang, Y., Rogaeva, E. A., Levesque, G., Ikeda, M., Chi, H., Lin, C., Li, G., Holman, K., et al. (1995) · Nature · doi:10.1038/375754a0 · Cited by 4,051 · cited 9×
“In AD, for instance, rare, fully penetrant autosomal dominant mutations in 3 genes (i.e. APP, PSEN1, and PSEN2) have been shown to cause the disease, while a common, incompletely penetrant susceptibility variant (i.e., ε4 in APOE; see below) significantly increases the risk for AD.”
BackgroundInfluential
Research works printed but not linked: 1
- [92]Prusiner, S.B. 1998. Prions. Proc. Natl. Acad. Sci. U. S. A. 95 :13363-13383.
Cited by
Items 101–200 of 678
Mulligan, V. K., & Chakrabartty, A. (2013) · Proteins: Structure, Function, and Bioinformatics · doi:10.1002/prot.24285 · Cited by 81
High familial risks for cerebral palsy implicate partial heritable aetiology
Hemminki, K., Li, X., Sundquist, K., & Sundquist, J. (2007) · Paediatric and Perinatal Epidemiology · doi:10.1111/j.1365-3016.2007.00798.x · Cited by 81
Reale, M., Kamal, M. A., Patruno, A., Costantini, E., D’Angelo, C., Pesce, M., & Greig, N. H. (2014) · PLoS ONE · doi:10.1371/journal.pone.0104973 · Cited by 86
“Whereas the occurrence of some chronic diseases are relatively uncommon (ALS, HD) and have long latency periods for known risk factors, for others – all be they abundant (AD, PD) - their etiologies remain poorly understood [1,2], which confounds the observation of potential associations, particularly when relying on m…”
BackgroundAlzheimer's Disease and Amyloid: Culprit or Coincidence?
Skaper, S. D. (2012) · International review of neurobiology · doi:10.1016/b978-0-12-386986-9.00011-9 · Cited by 91
“…AD pathogenesis, a concept derived from the identification of pathogenic mutations in patients with familial AD that are linked to Ab formation, as well as increased Ab levels and a higher frequency of AD in individuals with trisomy 21, who carry an additional APP allele (Bertram and Tanzi, 2005).”
BackgroundPridopidine activates neuroprotective pathways impaired in Huntington Disease
Geva, M., Kusko, R. L., Soares, H. D., Fowler, K. D., Birnberg, T., Barash, S., Wagner, A. M., Fine, T., Lysaght, A. C., Weiner, B., et al. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddw238 · Cited by 85
“Huntington disease (HD) is a neurodegenerative disease caused by a dominant trinucleotide repeat expansion in the huntingtin gene (1) and is estimated to affect 43,000 individuals in the US alone (2).”
BackgroundEric E Hall, M. H. S. (2014) · Journal of Alzheimer's Disease & Parkinsonism · doi:10.4172/2161-0460.1000137 · Cited by 79
“Significant increases in CMRgl are reported in bilateral lentiform nucleus, PCC, and parahippocampus [222], whereas significant reductions in CMRgl are observed in the temporal, parietal, frontal, occipital cortices and caudate of PD patients [223,224].”
BackgroundE3 Ubiquitin Ligases Neurobiological Mechanisms: Development to Degeneration
Upadhyay, A., Joshi, V., Amanullah, A., Mishra, R., Arora, N., Prasad, A., & Mishra, A. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00151 · Cited by 87
“Several aging-related changes and lateonset neurodegenerative disorders may also add up to the pathologies generated, either due to some genetic mutations, or structural and functional modifications in disease-associated proteins (Bertram and Tanzi, 2005; Esiri, 2007; Douglas and Dillin, 2010).”
BackgroundGenetic heterogeneity of Alzheimer's disease: Complexity and advances
Lambert, J., & Amouyel, P. (2007) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2007.05.015 · Cited by 87
“According to current estimates, APOE may be involved in less than 20% of the AD forms not inherited through Mendelian transmission (Bertram and Tanzi, 2005).”
BackgroundEdwards, I. R., Star, K., & Kiuru, A. (2007) · Drug Safety · doi:10.2165/00002018-200730060-00005 · Cited by 88
“trophic lateral sclerosis’, was reported for drugs in • ALS is a rare, fatal, progressive, degenerative the HMG-CoA reductase inhibitors group (accordmotor neurone disease with an overall prevalence ing to the anatomical therapeutic chemical (ATC) of about 5 in 100 000 individuals.[10] There is a classification).”
BackgroundThe Importance of NAD in Multiple Sclerosis
Penberthy, W., & Tsunoda, I. (2009) · Current Pharmaceutical Design · doi:10.2174/138161209787185751 · Cited by 75
“Dementia results from neurodegeneration most commonly from Alzheimer’s Disease followed by vascular dementia [344].”
BackgroundKountouras, J., Gavalas, E., Zavos, C., Stergiopoulos, C., Chatzopoulos, D., Kapetanakis, N., & Gisakis, D. (2006) · Medical Hypotheses · doi:10.1016/j.mehy.2006.06.052 · Cited by 85
“Genetic transmission in an autosomal dominant fashion has also been reported in AD [108].”
BackgroundTello, J. A., Williams, H., Eppler, R., Steinhilb, M. L., & Khanna, M. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.883358 · Cited by 83
Qing, X., Walter, J., Jarazo, J., Arias, J., Hillje, A., & Schwamborn, J. C. (2017) · Stem Cell Research · doi:10.1016/j.scr.2017.08.013 · Cited by 78
Sales, T. A., Prandi, I. G., de Castro, A. A., Leal, D. H. S., da Cunha, E. F. F., Kuča, K., & Ramalho, T. C. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20081829 · Cited by 75
“The neurodegenerative diseases onset take place mainly in people above the age of 45 years old [7,8].”
BackgroundGadhave, K., Kumar, D., Uversky, V. N., & Giri, R. (2021) · Medicinal Research Reviews · doi:10.1002/med.21719 · Cited by 68
Role of 5-hydroxymethylcytosine in neurodegeneration
Sherwani, S. I., & Khan, H. A. (2015) · Gene · doi:10.1016/j.gene.2015.06.052 · Cited by 75
“…toxicity have not been elucidated completely but it has been suggested that some SNCA mutations may quantitatively alter the normal protein function by doubling or tripling the α-synuclein gene (Bertram and Tanzi, 2005; Lazaro et al., 2014; Moussaud et al., 2014; Snead and Eliezer, 2014).”
BackgroundMethodInfluentialGarcía-Huerta, P., Troncoso-Escudero, P., Wu, D., Thiruvalluvan, A., Cisternas-Olmedo, M., Henríquez, D. R., Plate, L., Chaná‐Cuevas, P., Saquel, C., Thielen, P., et al. (2020) · Acta Neuropathologica · doi:10.1007/s00401-020-02183-1 · Cited by 72
Human induced pluripotent stem cells and neurodegenerative disease: prospects for novel therapies
Jung, Y. W., Hysolli, E., Kim, K., Tanaka, Y., & Park, I. (2012) · Current Opinion in Neurology · doi:10.1097/wco.0b013e3283518226 · Cited by 85
Nizzari, M., Thellung, S., Corsaro, A., Villa, V., Pagano, A., Porcile, C., Russo, C., & Florio, T. (2012) · Journal of Toxicology · doi:10.1155/2012/187297 · Cited by 70
“[21] L.”
BackgroundBoutin, H., Chauveau, F., Thominiaux, C., Kuhnast, B., Grégoire, M., Jan, S., Trebossen, R., Dollé, F., Tavitian, B., Mattner, F., et al. (2007) · Glia · doi:10.1002/glia.20562 · Cited by 67
Alzheimer’s Disease: A Clinical Practice-Oriented Review
Alves, L., Correia, A. S. A., Miguel, R., Alegria, P., & Bugalho, P. (2012) · Frontiers in Neurology · doi:10.3389/fneur.2012.00063 · Cited by 68
“Autosomal dominant disease is usually found in early onset AD families (Bertram and Tanzi, 2005).”
BackgroundKang, Y., Jung, H., Oh, J., & Song, D. (2016) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12580 · Cited by 68
“Every year, more than 10 million people globally are diagnosed with neurodegenerative diseases such as Alzheimer’s disease or PD [2].”
BackgroundAmyloid-β interrupts canonical Sonic hedgehog signaling by distorting primary cilia structure
Vorobyeva, A. G., & Saunders, A. J. (2018) · Cilia · doi:10.1186/s13630-018-0059-y · Cited by 67
Shared mechanisms among neurodegenerative diseases: from genetic factors to gene networks
Arneson, D., Zhang, Y., Yang, X., & Narayanan, M. (2018) · Journal of Genetics · doi:10.1007/s12041-018-0963-3 · Cited by 67
Molecular mechanisms of proteinopathies across neurodegenerative disease: a review
Marsh, A. (2019) · Neurological Research and Practice · doi:10.1186/s42466-019-0039-8 · Cited by 68
Wirz, K. T. S., Bossers, K., Stargardt, A., Kamphuis, W., Swaab, D. F., Hol, E. M., & Verhaagen, J. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.11.008 · Cited by 65
“Besides the sporadic form of AD, for which aging is themain risk factor, mutations in amyloid precursor protein (APP), presenilin 1 (PSEN1), and presenilin 2 (PSEN2) have been found to cause autosomal dominant early onset familial AD in a small number of families (Bertram and Tanzi, 2005).”
Geng, L., Zhang, T., Liu, W., & Chen, Y. (2018) · Neuroscience Letters · doi:10.1016/j.neulet.2018.03.037 · Cited by 68
CRISPR-Cas9-Based Technology and Its Relevance to Gene Editing in Parkinson’s Disease
Rahman, M. U., Bilal, M., Shah, J. A., Kaushik, A. K., Teissèdre, P., & Kujawska, M. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14061252 · Cited by 70
Interaction between -Synuclein and Other Proteins in Neurodegenerative Disorders
Jellinger, K. A. (2011) · The Scientific World JOURNAL · doi:10.1100/2011/371893 · Cited by 64
“Support for this concept stems from the identification of pathogenic mutations in patients with familial AD linked to Aβ formation and a higher frequency of AD in people with trisomy 21, who carry an additional APP allele [93].”
Fan, L., Tzen, K., Chen, Y., Chen, T., Lai, Y., Yen, R., Huang, Y.-Y., Shiue, C., Yang, S., & Chiu, M. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00175 · Cited by 68
“The epsilon four allele of apolipoprotein (ApoE4) has been identified as an independent risk factor for sporadic AD and a genetic factor that is associated with a lower age at disease onset (Bertram and Tanzi, 2005; Sando et al., 2008).”
BackgroundWidespread remodeling of proteome solubility in response to different protein homeostasis stresses
Sui, X., Pires, D. E. V., Ormsby, A. R., Cox, D., Nie, S., Vecchi, G., Vendruscolo, M., Ascher, D. B., Reid, G. E., & Hatters, D. M. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1912897117 · Cited by 63
“Indeed, dysfunctional protein aggregation and protein homeostasis imbalance are central pathological features of common neurodegenerative diseases including Alzheimer’s (AD), Parkinson’s (PD), Huntington’s, and motor neuron diseases (3, 4).”
BackgroundCheng, C.-S., Liu, T.-P., Chien, F.-C., Mou, C.-Y., Wu, S.-H., & Chen, Y.-P. (2019) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.9b02797 · Cited by 63
Prevention and Treatment of Alzheimer’s Disease: Biological Mechanisms of Exercise
McGurran, H., Glenn, J. M., Madero, E. N., & Bott, N. T. (2019) · Journal of Alzheimer’s Disease · doi:10.3233/jad-180958 · Cited by 63
“The vast majority of AD cases are sporadic, with geneticfactorsaccountingforlessthan5%ofallcases [7].”
Barmada, S. J., & Finkbeiner, S. (2010) · Reviews in the Neurosciences · doi:10.1515/revneuro.2010.21.4.251 · Cited by 61
“Amyotroph Lateral Scler 2009;10(5-6):324-31.”
Zhang, Z., & Cheng, Y. (2014) · The Scientific World Journal · doi:10.1155/2014/938348 · Cited by 61
“miR-16-1 Promotes the Aberrant 𝛼-Synuclein Accumulation in”
Chapter 9 Alzheimer's Disease Genetics
Bertram, L. (2009) · International review of neurobiology · doi:10.1016/s0074-7742(09)00409-7 · Cited by 72
Self-citationHistone H3 acetylation in the postmortem Parkinson’s disease primary motor cortex
Gebremedhin, K. G., & Rademacher, D. J. (2016) · Neuroscience Letters · doi:10.1016/j.neulet.2016.05.060 · Cited by 64
“Parkinson’s disease (PD) is a progressive neurological disorder affecting approximately 2% of the population 65 years old or older [4].”
BackgroundP5 eHealth: An Agenda for the Health Technologies of the Future
Pravettoni, G., & Triberti, S. (2019) · Springer eBooks · doi:10.1007/978-3-030-27994-3 · Cited by 68
Long-term proteasome dysfunction in the mouse brain by expression of aberrant ubiquitin
Fischer, D. F., van Dijk, R., van Tijn, P., Hobo, B., Verhage, M. C., van der Schors, R. C., Li, K. W., van Minnen, J., Hol, E. M., & van Leeuwen, F. W. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.06.009 · Cited by 66
Mapping the new frontier: complex genetic disorders
Mayeux, R. P. (2005) · Journal of Clinical Investigation · doi:10.1172/jci25421 · Cited by 61
“org Volume 115 Number 6 June 2005 cursor protein and presenilin I and II lead to an overproduction of amyloid β protein, which is deposited in the brains of all patients with Alzheimer disease, regardless of the etiology (3).”
BackgroundGenetic susceptibility testing for neurodegenerative diseases: Ethical and practice issues
Roberts, J. S., & Uhlmann, W. R. (2013) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2013.02.005 · Cited by 59
Proteostasis disturbance in amyotrophic lateral sclerosis
Medinas, D. B., Valenzuela, V., & Hetz, C. A. (2017) · Human Molecular Genetics · doi:10.1093/hmg/ddx274 · Cited by 74
Protein aggregation in cell biology: An aggregomics perspective of health and disease
Cox, D., Raeburn, C., Sui, X., & Hatters, D. M. (2018) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2018.05.003 · Cited by 65
Herpes Simplex Virus Vectors for Gene Transfer to the Central Nervous System
Artusi, S., Miyagawa, Y., Goins, W. F., Cohen, J. B., & Glorioso, J. C. (2018) · Diseases · doi:10.3390/diseases6030074 · Cited by 59
“For example, early-onset AD has been linked to mutations in the genes encoding amyloid precursor protein (APP) and the presenilins (PS-1 and PS-2) involved in amyloid-β processing [3,4], while the ε4 allele of the apolipoprotein E gene has been identified as a risk factor for late-onset AD [8–10].”
BackgroundCo-delivery of synergistic antioxidants from food sources for the prevention of oxidative stress
Fleming, E., & Luo, Y. (2021) · Journal of Agriculture and Food Research · doi:10.1016/j.jafr.2021.100107 · Cited by 75
Gu, Y., Zhao, X., Zhang, N., Yang, Y., Yi, Y., Shao, Q.-H., Liu, M.-X., & Zhang, X.-L. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102577 · Cited by 70
Iijima, K., & Iijima‐Ando, K. (2008) · Journal of Alzheimer s Disease · doi:10.3233/jad-2008-15402 · Cited by 73
“Less than 10% of all AD cases are inherited in an autosomal dominant manner [5].”
Eriksson, U. K., Pedersen, N. L., Reynolds, C. A., Hong, M.-G., Prince, J. A., Gatz, M., Dickman, P. W., & Bennet, A. M. (2011) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-101671 · Cited by 58
“Whereasearly-onsetfamilialAD(which representslessthan1%ofallADcases)iscaused inanyindividualbyoneofseveralautosomaldomi-nantgenes manycommonvariationsinalargenumberofgenes withlowpenetrance[5].”
Loreth, D., Ozmen, L., Revel, F. G., Knoflach, F., Wetzel, P., Frotscher, M., Metzger, F., & Kretz, O. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.03.011 · Cited by 57
“FAD is associatedwith geneticmutations in amyloid precursor protein (APP) and presenilin (PS) 1 or 2 (Bertram and Tanzi, 2005; Goate, 2006; Sherrington et al., 1995), makingmodels based on these human mutations highly relevant for investigations on the pathophysiology of FAD.”
BackgroundTowards Unveiling the Genetics of Neurodegenerative Diseases
Lill, C., & Bertram, L. (2011) · Seminars in Neurology · doi:10.1055/s-0031-1299791 · Cited by 57
“GENETIC ASPECTS OF COMMON NEURODEGENERATIVE DISEASES Many neurodegenerative diseases share several clinical, pathologic, and molecular characteristics.(1) Clinically, these disorders are often represented by an insidious onset during adulthood, after which they progress at varying rates, ultimately leading to severe p…”
BackgroundSelf-citationYeast models of Parkinson’s disease-associated molecular pathologies
Tenreiro, S., Franssens, V., Winderickx, J., & Outeiro, T. F. (2017) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2017.01.013 · Cited by 68
Dai, R., Sun, Y., Su, R., & Gao, H. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113576 · Cited by 63
The neuronal sortilin-related receptor gene SORL1 and late-onset Alzheimer’s disease
Lee, J. H., Barral, S., & Reitz, C. (2008) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-008-0060-8 · Cited by 56
The last neuronal division: a unifying hypothesis for the pathogenesis of Alzheimer's disease
Nagy, Z. (2005) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2005.tb00485.x · Cited by 56
“The identification of presenilin (PS1 and PS2) mutations associated with early onset AD [10–12] was 'naturally' followed by the search for links between the presenilins and amyloid [13] and the role of the presenilin mutations in the pathogenesis of AD is attributed, even in some recent reviews, solely to their effect…”
BackgroundFunctional analyses of major cancer-related signaling pathways in Alzheimer's disease etiology
Guo, J., Cheng, J., North, B. J., & Wei, W. (2017) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2017.07.001 · Cited by 55
Understanding and exploiting the roles of O-GlcNAc in neurodegenerative diseases
Pratt, M. R., & Vocadlo, D. J. (2023) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.105411 · Cited by 59
“…are both sporadic and late onset, but speci fi c mutations in the genes encoding various disease-associated proteins are risk factors for NDDs that can result in symptomatic disease earlier in life and in some cases are causative, giving rise to early onset familial forms of these diseases (13).”
BackgroundDetecting neurodegenerative disorders from web search signals
White, R. W., Doraiswamy, P. M., & Horvitz, E. (2018) · npj Digital Medicine · doi:10.1038/s41746-018-0016-6 · Cited by 54
“Cursor position data were sampled while the cursor was in motion; (3) Repetition: presence of repeat queries, repeat result clicks, and repeat query-result click pairs, and (4) Risk Factors: presence of risk factors derived from previous work (e.g., 12 – 14 ).”
BackgroundGut-brain axis and neurodegeneration: mechanisms and therapeutic potentials
Park, K. J., & Gao, Y. (2024) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1481390 · Cited by 71
Systems biology of neurodegenerative diseases
Wood, L. B., Winslow, A. R., & Strasser, S. D. (2015) · Integrative Biology · doi:10.1039/c5ib00031a · Cited by 53
Sheta, E. A., Appel, S. H., & Goldknopf, I. L. (2006) · Expert Review of Proteomics · doi:10.1586/14789450.3.1.45 · Cited by 57
“Early-onset familial AD represents a small fraction of all AD cases (≤5%), dominates in younger age ( 10 ,11].”
BackgroundAccelerating neuronal aging in in vitro model brain disorders: a focus on reactive oxygen species
Campos, P. B., Paulsen, B. S., & Rehen, S. K. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00292 · Cited by 52
“The deposition of amyloid-β (Aβ) derived from the cleavage of amyloid precursor protein (APP) by β and γ-secretases and the hyperphosphorylation of Tau (a microtubule-associated protein) are the hallmarks of AD (Bertram and Tanzi, 2005; Jin et al., 2011).”
BackgroundSirtuin-2 Protects Neural Cells from Oxidative Stress and Is Elevated in Neurodegeneration
Singh, P., Hanson, P. S., & Morris, C. M. (2017) · Parkinson s Disease · doi:10.1155/2017/2643587 · Cited by 52
“Parkinson’s disease is the most common neurodegenerative movement disorder [8, 9] and typically involves progressive loss of dopaminergic (DA) neurones in the substantia nigra (SN) and accumulation of cytoplasmic inclusions, Lewy bodies (LB) and Lewy neurites composed of alpha-synuclein (α-synuclein) [10].”
BackgroundLipid-Based Nanocarriers via Nose-to-Brain Pathway for Central Nervous System Disorders
Nguyen, T. T., Nguyen, T. T. D., An, T. N. M., & Giau, V. V. (2021) · Neurochemical Research · doi:10.1007/s11064-021-03488-7 · Cited by 55
Is lithium neuroprotective? An updated mechanistic illustrated review
Ghanaatfar, F., Ghanaatfar, A., Isapour, P., Farokhi, N., Bozorgniahosseini, S., Javadi, M., Gholami, M., Ulloa, L., Coleman‐Fuller, N., & Motaghinejad, M. (2022) · Fundamental and Clinical Pharmacology · doi:10.1111/fcp.12826 · Cited by 58
Targeted Suppression of Chaperone-Mediated Autophagy by miR-320a Promotes α-Synuclein Aggregation
Li, G., Yang, H., Zhu, D., Huang, H., Liu, G., & Lun, P. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms150915845 · Cited by 60
“Parkinson’s disease (PD) is the second most common disorder of the central nervous system in humans [1], with a prominent characteristic of dopaminergic cells degeneration within the substantia nigra pars compacta (SNpc) [2] and the cytoplasmic accumulation of proteinaceous material within aggregates called Lewy bodie…”
BackgroundNecroptosis in amyotrophic lateral sclerosis and other neurological disorders
Morrice, J. R., Gregory, C. Y., & Shaw, C. A. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2016.11.025 · Cited by 60
Yang, Y., Qin, M., Bao, P., Xu, W., & Xu, J. (2017) · PLoS ONE · doi:10.1371/journal.pone.0180892 · Cited by 56
Double stranded RNA activated EIF2 α kinase (EIF2AK2; PKR) is associated with Alzheimer's disease
Bullido, M. J., Martínez-García, A., Tenorio, R., Sastre, I., Muñoz, D. G., Frank, A., & Valdivieso, F. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.02.023 · Cited by 51
Complement receptor 1 polymorphisms and risk of late-onset Alzheimer's disease
Zhang, Q., Yu, J., Zhu, Q.-X., Zhang, W., Wu, Z., Miao, D., & Tan, L. (2010) · Brain Research · doi:10.1016/j.brainres.2010.06.018 · Cited by 58
Aggregation of neurodegenerative disease in ALS kindreds
Fallis, B. A., & Hardiman, O. M. (2008) · Amyotrophic Lateral Sclerosis · doi:10.1080/17482960802209664 · Cited by 57
“Up to 10% of cases are known to be genetic (2).”
BackgroundQu, Y., Liu, Y., Noor, A. F., Tran, J., & Li, R. (2019) · Neural Regeneration Research · doi:10.4103/1673-5374.250570 · Cited by 56
“However, amyotrophic lateral sclerosis is a disease which leads to paralysis and premature death (Bertram and Tanzi, 2005; Yamashita et al., 2013).”
Copy Number Variants in Alzheimer’s Disease
Cuccaro, D., Marco, E. V. D., Cittadella, R., & Cavallaro, S. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160469 · Cited by 55
“The disease can be classified into two types, depending on the age of onset: early-onset (EOAD) that occurs before 65 years of age and accounts for less than 5% of all cases [3], and late-onset (LOAD, >65 years) which is the most common form.”
BackgroundSharma, M., Mueller, J. C., Zimprich, A., Lichtner, P., Hofer, A., Leitner, P., Maass, S., Berg, D., Dürr, A., Bonifati, V, et al. (2006) · Journal of Medical Genetics · doi:10.1136/jmg.2005.039149 · Cited by 49
Prado-Audelo, M. L. D., Magaña, J. J., Mejía-Contreras, B. A., Borbolla‐Jiménez, F. V., Giraldo‐Gómez, D. M., Piña-Barba, M. C., Quintanar‐Guerrero, D., & Leyva‐Gómez, G. (2019) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2019.05.042 · Cited by 48
Brief update on different roles of tau in neurodegeneration
Ittner, A., Ke, Y. D., Eersel, J. V., Gladbach, A., Götz, J., & Ittner, L. M. (2011) · IUBMB Life · doi:10.1002/iub.467 · Cited by 47
“Abbreviations AD, Alzheimer’s disease; FTLD, frontotemporal lobar degeneration; NFT, neurofibrillary tangle; MAPT, microtubule-associated protein tau gene; Ab, amyloid b; APP, Ab-precursor protein; FTD, frontotemporal dementia; FTLD-TAU, FTLD with tau deposition; FTDP-17, FTD with parkinsonism linked to chromosome 17;…”
BackgroundNature versus Nurture: Death of a Dogma, and the Road Ahead
Traynor, B. J., & Singleton, A. B. (2010) · Neuron · doi:10.1016/j.neuron.2010.10.002 · Cited by 47
Codon Usage Pattern of Genes Involved in Central Nervous System
Uddin, A., & Chakraborty, S. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-1173-y · Cited by 50
“Fronto temporal dementia (FTD) with parkinsonism brings about a mutation in the microtubuleassociated protein tau [2].”
BackgroundA review on neuropharmacological role of erucic acid: an omega-9 fatty acid from edible oils
Kumar, J. B. S., & Sharma, B. (2020) · Nutritional Neuroscience · doi:10.1080/1028415x.2020.1831262 · Cited by 54
Targeting ApoE4/ApoE receptor LRP1 in Alzheimer's disease
Martiskainen, H., Haapasalo, A., Kurkinen, K. M., Pihlajamäki, J., Soininen, H., & Hiltunen, M. (2013) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2013.789862 · Cited by 46
“Mutations in the amyloid precursor protein (APP) and presenilin (PSEN) genes are responsible for rare autosomal dominant form of the disease, which usually appears before the age of 65 years [4].”
BackgroundCellular and Molecular Aspects of Parkinson Treatment: Future Therapeutic Perspectives
Jamebozorgi, K., Taghizadeh, E., Rostami, D., Pormasoumi, H., Barreto, G. E., Hayat, S. M. G., & Sahebkar, A. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-1419-8 · Cited by 50
Targeting of the unfolded protein response (UPR) as therapy for Parkinson's disease
Martinez, A. N., López, N., González, C., & Hetz, C. A. (2019) · Biology of the Cell · doi:10.1111/boc.201800068 · Cited by 49
“These diseases are collectively referred as proteinopathies or protein misfolded disorders (PMDs) [Soto, 2003; Bertram and Tanzi, 2005; Aguzzi and O’Connor, 2010].”
BackgroundResultInfluentialNaghavi, N., & Wade, E. (2021) · IEEE Journal of Biomedical and Health Informatics · doi:10.1109/jbhi.2021.3103071 · Cited by 55
Amyloid–β peptides time-dependent structural modifications: AFM and voltammetric characterization
Enache, T. A., Paquim, A.-M. C., & Oliveira‐Brett, A. M. (2016) · Analytica Chimica Acta · doi:10.1016/j.aca.2016.04.015 · Cited by 46
Gene Therapy Strategies to Restore ER Proteostasis in Disease
Valenzuela, V., Jackson, K. L., Sardi, S. P., & Hetz, C. A. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.04.004 · Cited by 56
“) and are now classified as protein misfolding disorders.(28,29) Importantly, the presence of chronic ER stress markers is an emerging signature of most of these diseases, as well as other conditions, such as spinal cord injury, brain ischemia,(33) and multiple sclerosis.”
BackgroundHu, D., Liu, Z., & Qi, X. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.746873 · Cited by 46
Monda, A., Torre, M. E. L., Messina, A., Maio, G. D., Monda, V., Moscatelli, F., Stefano, M. D., Marra, M. L., di Padova, M., Dipace, A., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1425816 · Cited by 51
“Ketone bodies, once synthesized following the ketosis process, can be used as the main source of energy especially for the main vital organs such as the heart, muscle tissue, kidneys but above all the brain (23, 24).”
BackgroundIs membrane homeostasis the missing link between inflammation and neurodegenerative diseases?
de Groot, N. S., & Torrent, M. (2015) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-2038-4 · Cited by 46
Immune-mediated processes in neurodegeneration: where do we stand?
Fakhoury, M. (2016) · Journal of Neurology · doi:10.1007/s00415-016-8052-0 · Cited by 43
“Parkinson disease (PD), and in SOD1 causing amyloid lateral sclerosis (ALS) [1].”
BackgroundEnteral feeding in neurological disorders
Stavroulakis, T., & McDermott, C. J. (2016) · Practical Neurology · doi:10.1136/practneurol-2016-001408 · Cited by 52
“Enteral feeding in Parkinson╆s disease ゅPDょ Parkinson╆s disease ゅPDょ is the second most common adult onset neurodegenerative disorder,[31] with an incidence of 84 per 100,000 person-years for people aged over 50 years in the UK.”
BackgroundInfluentialKassem, L. M., Ibrahim, N., & Farhana, S. A. (2020) · Journal of Nanotechnology · doi:10.1155/2020/8147080 · Cited by 50
“more than 50 yrs and may jump to 50% in adults more than 70 yrs [4].”
BackgroundCell guidance on peptide micropatterned silk fibroin scaffolds
Sun, W., Taylor, C. S., Zhang, Y., Gregory, D. A., Tomeh, M. A., Haycock, J. W., Smith, P. J., Wang, F., Xia, Q., & Zhao, X. (2021) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2021.06.086 · Cited by 46
Raman, S., Brookhouser, N., & Brafman, D. A. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104788 · Cited by 42
Recent updates on structural insights of MAO-B inhibitors: a review on target-based approach
Baweja, G. S., Gupta, S., Kumar, B., Patel, P., & Asati, V. (2023) · Molecular Diversity · doi:10.1007/s11030-023-10634-6 · Cited by 44
“The most important mechanisms involved in the development of Parkinson’s disease include misfolded aggregates of proteins, oxidative stress, mitochondrial damage, failure of protein clearance pathway, neuroinflammation, and genetic mutation [17, 18].”
Neuro-Vulnerability in Energy Metabolism Regulation: A Comprehensive Narrative Review
Clemente‐Suárez, V. J., Beltrán-Velasco, A. I., Redondo-Flórez, L., Martín-Rodríguez, A., Sepulveda, R. A. Y., & Tornero-Aguilera, J. F. (2023) · Nutrients · doi:10.3390/nu15143106 · Cited by 50
“Likewise, a genetic predisposition [187], environmental factors [8], free radical production [188], excitotoxicity, neuroinflammation, disruption of the calcium”
BackgroundA platelet protein biochip rapidly detects an Alzheimer’s disease-specific phenotype
Veitinger, M., Oehler, R., Umlauf, E., Baumgartner, R., Schmidt, G., Gerner, C., Babeluk, R., Attems, J., Mitulovic, G., Rappold, E., et al. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1341-8 · Cited by 41
“787 (Table 3, model 0) for the APOE ε4 allele count reflects limited diagnostic sensitivity/ specificity [7].”
BackgroundMAZZIO, E. A., Close, F. T., & Soliman, K. F. A. (2011) · International Journal of Molecular Sciences · doi:10.3390/ijms12010506 · Cited by 46
“G2019S, park-1/Synuclein (SNCA), ubiquitin-carboxy-terminal-hydrolase L1, parkin (Del3-5, T240R, Q311X) [15–18], ATP13A2 (Park 9), β-glucocerebrosidase and mitochondrial proteins such as park 13 Omi/Htra2, Complex I [19–22].”
Familial risks for common diseases: Etiologic clues and guidance to gene identification
Hemminki, K., Li, X., Sundquist, K., & Sundquist, J. (2008) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2008.01.002 · Cited by 42
Inflammation in Neurodegenerative Disorders: Friend or Foe?
Galimberti, D., Fenoglio, C., & Scarpini, E. (2008) · Current Aging Sciencee · doi:10.2174/1874609810801010030 · Cited by 41
Die Alzheimer‐Demenz: von der Pathologie zu therapeutischen Ansätzen
Jakob‐Roetne, R., & Jacobsen, H. (2009) · Angewandte Chemie · doi:10.1002/ange.200802808 · Cited by 41
Renani, P. G., Taheri, F., Rostami, D., Farahani, N., Abdolkarimi, H., Abdollahi, E., Taghizadeh, E., & Hayat, S. M. G. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.28622 · Cited by 45
“Epidemiological studies on the disease have shown that PD is a global concern, accounting for 1–2% of the elderly over the age of 65 years and 4–5% of individuals over the age of 85 years (Bertram & Tanzi, 2005; Hirsch, Jette, Frolkis, Steeves, & Pringsheim, 2016).”
Background
Metadata
- Authors
- Bertram, L.
- Affiliations
- Harvard University (US)
- Corresponding author
- Bertram, L.
- ORCID
- Bertram, L.
- Venue
- Journal of Clinical Investigation
- Published
- 2005-06-01
- Volume
- 115
- Issue
- 6
- Pages
- 1449-1457
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC1137006
- OpenAlex
- W2110054485
- Cited by
- 680
- References
- 106
- Citations by year
- 2026: 17 · 2025: 29 · 2024: 40 · 2023: 48 · 2022: 48 · 2021: 40 · 2020: 44 · 2019: 37 · 2018: 46 · 2017: 41 · 2016: 36 · 2015: 20 · 2014: 25 · 2013: 25 · 2012: 34
- FWCI
- 2.89
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Alzheimer's Association
- Massachusetts General Hospital
- National Alliance for Research on Schizophrenia and Depression
- Deutsche Forschungsgemeinschaft
- National Institute on Aging
- National Institute of Mental Health
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Keywords
- neurodegenerative diseases, genetic epidemiology, Alzheimer's disease, Parkinson's disease, dementia with Lewy bodies, frontotemporal dementia, amyotrophic lateral sclerosis, Huntington's disease, prion disease, common disease-common variant hypothesis, complex disease genetics, familial aggregation, genetic risk factors, single nucleotide polymorphisms, gene-environment interaction, genetic heterogeneity, pathogenesis, amyloid precursor protein, alpha-synuclein, tau protein
- MeSH terms
- Chromosome Mapping, Nerve Degeneration, Molecular Epidemiology, Neurodegenerative Diseases, Genetic Predisposition to Disease, Physical Chromosome Mapping
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.